Trial Investigating Ustekinumab for Systemic Lupus Erythematosus Discontinued
Janssen has decided to discontinue the phase 3 LOTUS study evaluating ustekinumab (Stelara®) for the treatment of systemic lupus erythematosus.
Lupus
SLE May Have Early Effect on Peripheral Nerve Function Before Electrophysiologic or Clinical Neuropathy Development
Researchers determined whether SLE could have an early effect on peripheral nerve function before the development of electrophysiologic abnormalities.
Lack of EULAR/ERA-EDTA Response Predicts Chronic Kidney Disease in Patients With Lupus Nephritis
Researchers evaluated EULAR/ERA-EDTA response to therapy in patients with lupus nephritis.
Inclusion of Non-Criteria Features to SLE Classification Improves Diagnostic Accuracy
Researchers identified criteria and non-criteria features associated with SLE, which can be used in classification criteria.
Belimumab Plus Standard Lupus Nephritis Therapy Improves Renal Responses
Adding belimumab to standard therapy for lupus nephritis is associated with better renal outcomes compared with standard therapy alone.
Interferon Inhibition With Anifrolumab Reduces Disease Activity in Systemic Lupus Erythematosus
An investigational type 1 interferon receptor inhibitor was associated with significant reduction in disease activity in patients with systemic lupus erythematosus.
High Serum Albumin Levels Have a Protective Effect on Mental Health in Patients With Juvenile SLE
Study findings from EULAR 2020 suggest that higher albumin levels provide a potentially protective effect on mental health in juvenile SLE.
Considerations for Hydroxychloroquine Use in Patients With Diabetes
Careful consideration should be taken before using hydroxychloroquine in patients with diabetes, particularly in the context of COVID-19.
Voclosporin NDA for Lupus Nephritis Submitted to the FDA
The NDA for voclosporin has been submitted to the Food and Drug Administration (FDA) for the treatment for lupus nephritis.
WHO Suspends Testing of Hydroxychloroquine in Patients With COVID-19
The WHO has suspended use of the antimalarial drug hydroxychloroquine in a clinical trial of treatments of COVID-19 after a study revealed that patients taking the drug are at increased risk for death and serious heart problems.
-
Loading...
-
Loading...
Next post in General Rheumatology
